Evaluation of Serum Nesfatin-1 Levels in Women with Polycystic Ovarian Syndrome and Estimating Its Correlation with Body Mass Index and Clinico-metabolic Profile

Background: Polycystic ovarian syndrome (PCOS) is a diverse condition marked by irregular menstruation, hyperandrogenism, and recurrent anovulation. An incidence of 6% to 20% of PCOS in women of reproductive age has been reported. Nesfatin-1 is a potent anorexigenic peptide having antihyperglycemic effects and is associated with energy balance and homeostasis, glucose metabolism, obesity, and probably gonadal functions. Nesfatin-1 is related to obesity, insulin resistance, and appetite. Nesfatin-1 is associated with insulin resistance, body mass index, diabetic inflammatory stimulation, hypertension, and PCOS. This study aims to evaluate the serum Nesfatin-1 levels in women with Polycystic Ovarian Syndrome and correlate with Body Mass Index, clinical and metabolic profile.

Materials and Methods: This will be a prospective Hospital-based observational study conducted at AVBRH in the Department of Obstetrics and Gynecology. A total of 96 women of reproductive age (15-45 years) will be enrolled. Detailed history of the menstrual cycle, obstetric history, background, medical and family history, and any primary care and inquiries will be documented. The general and systemic examination will be done to note any clinical evidence of hyperandrogenisms like acne, alopecia, acanthosis nigricans or hirsutism. The Ferriman-Gallwey Score (FGS) will be calculated. The ELISA method will be used for the calculation of N1. Serum Nesfatin-1 values will be correlated with clinical and metabolic profiles divided in the lean versus obese PCOS group. Data will be entered into a predetermined, pretested proforma and analyzed with appropriate statistical tests.

Expected Results: The levels of Serum Nesfatin in PCOS patients are expected to be abnormal. We will measure sensitivity, specificity, positive and negative predictive value, and efficacy. We will analyze the difference of results between lean PCOS and Obese PCOS and association with the clinico-metabolic profile.